Piramal Pharma Q2 Results Live: Profit Rises by 350% YoY- Dilli Dehat se


Piramal Pharma Q2 Results Live : Piramal Pharma declared their Q2 results on 23 Oct, 2024, showcasing robust financial performance. The company’s topline saw a significant increase of 17.28% year-over-year, while profits skyrocketed by an impressive 350% during the same period.

In comparison to the previous quarter, Piramal Pharma’s revenue grew by 14.89%, and profit surged by 125.49%. This quarter’s results are a testament to the company’s effective operational strategies and market positioning.

Notably, the Selling, General & Administrative (SG&A) expenses saw a decline of 3.48% quarter-over-quarter, although they increased by 8.43% year-over-year, reflecting the company’s focus on cost management amidst growth.

Operating income also witnessed a commendable rise, up by 41.83% sequentially and 21.27% year-over-year, indicating a solid operational performance. The Earnings Per Share (EPS) for Q2 stood at 0.17, which marks a remarkable increase of 325% year-over-year.

Despite a slight dip of -6.19% in the last week, Piramal Pharma has delivered a staggering return of 57.11% over the last six months and 57% year-to-date. Currently, the company’s market cap stands at 28,770.91 Cr, with a 52-week high of 243.99 and a low of 87.5.

As of 24 Oct, 2024, the outlook for Piramal Pharma appears optimistic, with 3 out of 5 analysts giving a Buy rating and 2 analysts recommending a Strong Buy. The consensus recommendation remains a Strong Buy, reflecting confidence in the company’s future performance.

Piramal Pharma Financials

Period Q2 Q1 Q-o-Q Growth Q2 Y-o-Y Growth
Total Revenue 2241.75 1951.14 +14.89% 1911.38 +17.28%
Selling/ General/ Admin Expenses Total 559.53 579.69 -3.48% 516.03 +8.43%
Depreciation/ Amortization 192.22 184.55 +4.16% 184.51 +4.18%
Total Operating Expense 1487.11 1419.07 +4.79% 1289.08 +15.36%
Operating Income 754.64 532.07 +41.83% 622.3 +21.27%
Net Income Before Taxes 120.12 -45.08 +366.46% 39.56 +203.64%
Net Income 22.59 -88.64 +125.49% 5.02 +350%
Diluted Normalized EPS 0.17 -0.67 +125.37% 0.04 +325%
Stay updated on quarterly results with our results calendar



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *